We are dead in 15 months

Quote

Anonymous

Guest
Just spoke with lead researcher for TMC-435 and he confirmed that the drug will be approved by the FDA in the 3rd quarter of 2013. That is only 15 months away! He told me I better start looking for a new job soon because no one will use Incivek (even if we get BID) because TMC-435 is QD and no anemia! Is this true? Has anyone else heard this?
 






Anonymous said:
Just spoke with lead researcher for TMC-435 and he confirmed that the drug will be approved by the FDA in the 3rd quarter of 2013. That is only 15 months away! He told me I better start looking for a new job soon because no one will use Incivek (even if we get BID) because TMC-435 is QD and no anemia! Is this true? Has anyone else heard this?
Click to expand...

Ill cross that bridge when get to it meanwhile I'll enjoy kicking some more merck butt with bid this fall
 






Anonymous said:
Ill cross that bridge when get to it meanwhile I'll enjoy kicking some more merck butt with bid this fall
Click to expand...

Me too. Awesome that options worth something again. Any idea about coformulating VX-222 and Incivek soon? That would be a kick ass combo that would knock out Gilead. Plus we have the connections with doctors, not Gilead.
 






Anonymous said:
Just spoke with lead researcher for TMC-435 and he confirmed that the drug will be approved by the FDA in the 3rd quarter of 2013. That is only 15 months away! He told me I better start looking for a new job soon because no one will use Incivek (even if we get BID) because TMC-435 is QD and no anemia! Is this true? Has anyone else heard this?
Click to expand...

This is news to you? You must be in one of those hick territories where docs are still treating and your wife is your sister. Get a clue moron.
 






I would not worry about the competition from a protease inhibitor like TMC-435 that so far requires both IFN and ribavirin to acheive SVR. The market for next gen hep C that has any future is an IFN free combination regimen. At EASL, Bloomberg interviewed the head of Jansenn's hep C program, and he expressed interest in partnering with Vertex to develop future combinations of IFN free hep C treatment regimens. It's the Alios nucs data, and the IFN free combination data with Incivek and VX 222 with riba that hold the keys to Vertex being able to compete in the next generation of hep C therapies coming in 2014 and we'll be hearing about that in just a few weeks. You may have three or four drugs to sell in a few years for treatment of the different subpopulations of hep C patients if the coming Phase 1 Alios data is competitive. In the meantime, you currently have the best in class direct acting anti-viral on the market, which will soon get approval for BID dosing, and approved indications to treat subpopulations like HIV coinfected patients (which numbers over three hundred thousand such patients in the U.S. alone) where Victrellis can't compete.
 






Anonymous said:
I would not worry about the competition from a protease inhibitor like TMC-435 that so far requires both IFN and ribavirin to acheive SVR. The market for next gen hep C that has any future is an IFN free combination regimen. At EASL, Bloomberg interviewed the head of Jansenn's hep C program, and he expressed interest in partnering with Vertex to develop future combinations of IFN free hep C treatment regimens. It's the Alios nucs data, and the IFN free combination data with Incivek and VX 222 with riba that hold the keys to Vertex being able to compete in the next generation of hep C therapies coming in 2014 and we'll be hearing about that in just a few weeks. You may have three or four drugs to sell in a few years for treatment of the different subpopulations of hep C patients if the coming Phase 1 Alios data is competitive. In the meantime, you currently have the best in class direct acting anti-viral on the market, which will soon get approval for BID dosing, and approved indications to treat subpopulations like HIV coinfected patients (which numbers over three hundred thousand such patients in the U.S. alone) where Victrellis can't compete.
Click to expand...

This post is just full of inaccuracies/lies. Wow
 






I personally don't see anyone using Incivek, even if it is BID after TMC-435 comes out. QD, no anemia, no rash - that is the protease inhibitor that will be used with peg & riba. Also, as more oral agents come out, there will be data on TMC-435 with GS-7977 (phase II) and BMS' daclatasvir (phase III) so Vertex will be dead in HCV after TMC-435 comes out.

VX-222 is not very potent and low barrier to resistance and phase I is well, phase I. Even with positive data, you won't see any drug currently in phase I for a minimum of 5 years. If you think Vertex will keep all of us very well paid reps between the time period of TMC-435 and the (hopeful) launch of the nucs then you are dreaming. That would be a dead time period of around 4 years.

I'm trying to catch on with Janssen or Gilead. That's the future. Goodbye Vertex.
 


















Ahhhh, anyone seen the protocols for the ongoing studies? Ya, none are using telaprevir. They are all using boceprevir, in order to avoid the side effects. Tha drug is dead when new agents come out. Why would a company use a drug that has such a horrible side effect profile. It would just taint the data from the new drug therapy. Both boceprevir and telaprevir are going to be non existent in the next few years. Boceprevir will just take a bit longer to disappear.
 






both of the PIs out there now will be dead when TMC-435 comes out - both Incivek and boceprevir. We may come out with BID before TMC-435 comes out, but QD beats BID.

Oh, and did they come up with any way of getting rid of the anemia and rash with the BID formulation? Because even if Incivek was QD it would be killed by TMC-435 on those two issues alone.

If anyone has a recruiter working with Janssen or Gilead, please post on the site!
 










































Just reading through droves of ignorant, cocky posts from those who couldn't see the writing on the wall. SOC including the PIs have had a limited shelf life for years. If you weren't reading the clinical trials of the upcoming drugs in this class and using this info to make a good career move and leave, shame on you.

As for the non-compete, it was nothing but a paper dragon with paper teeth. Crayons and lawyer threats might have made it look fierce but it was NEVER enforceable - at your level the law would say you never had secrets that could betray the company.

If you were desperate and needed a job, there was no shame in taking this gig. But if you left GILD, Merck, Etc for greener pastures, you should have see years ago that this was a dead end street and it shouldn't be a surprise that they were as Nasty as they were when they cut you; these were the same sharks who insisted on the non-compete before you came on.

As an outsider, this has been fascinating to watch and I feel badly about how things went down, but the overconfidence in spite of all the evidence that this was a very short term endeavor is reminiscent of the emperor and his clothes.

Good luck to all.
 






Anonymous said:
Just reading through droves of ignorant, cocky posts from those who couldn't see the writing on the wall. SOC including the PIs have had a limited shelf life for years. If you weren't reading the clinical trials of the upcoming drugs in this class and using this info to make a good career move and leave, shame on you.

As for the non-compete, it was nothing but a paper dragon with paper teeth. Crayons and lawyer threats might have made it look fierce but it was NEVER enforceable - at your level the law would say you never had secrets that could betray the company.

If you were desperate and needed a job, there was no shame in taking this gig. But if you left GILD, Merck, Etc for greener pastures, you should have see years ago that this was a dead end street and it shouldn't be a surprise that they were as Nasty as they were when they cut you; these were the same sharks who insisted on the non-compete before you came on.

As an outsider, this has been fascinating to watch and I feel badly about how things went down, but the overconfidence in spite of all the evidence that this was a very short term endeavor is reminiscent of the emperor and his clothes.

Good luck to all.
Click to expand...

Hmmm.....sounds like your a thinker... Thought about Idenix?
 






Anonymous said:
Hmmm.....sounds like your a thinker... Thought about Idenix?
Click to expand...

Many times and was burned 50% of them. They are years behind the current pack of HCV leaders and won't catch up. All of the HCV players are quite obvious now. Those like Idenix who are years behind and yet talked about as if the will be relevant in the market are no different than the Sirens on the Island of FaiaKes. Do you know this story?
 






Top Bottom
Back
Quote